The DOI matches its Crossref record; 212 of the 212 references it cites were found in a registry or an index.
Androgen Signaling in Prostate Cancer
Open accessAbstract
The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer. Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has remained a mainstay of therapy for advanced disease. However, progression to castration-resistant prostate cancer (CRPC) typically follows and is largely the result of restored androgen signaling. Efforts to understand the mechanisms behind CRPC have revealed new insights into dysregulated androgen signaling and intratumoral androgen synthesis, which has ultimately led to the development of several novel androgen receptor (AR)-directed therapies for CRPC. However, emergence of resistance to these newer agents has also galvanized new directions in investigations of prereceptor and postreceptor AR regulation. Here, we review our current understanding of AR signaling as it pertains to the biology and natural history of prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“…such as the potent second-generation competitive AR antagonist enzalutamide (Scher et al. 2012; Beer et al. 2014) and the androgen synthesis inhibitor abiraterone acetate (de Bono et al. 2011; Ryan et al. 2015), have provided the highest level of clinical evidence for this evolving paradigm.”
BackgroundRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
A signature motif in transcriptional co-activators mediates binding to nuclear receptors
Heery, D. M., Kalkhoven, E., Hoare, S., & Parker, M. G. (1997) · Nature · doi:10.1038/42750 · Cited by 2,128
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P., White, T. A., Stojanov, P., Van Allen, E., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,558
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Huggins, C., & Hodges, C. V. (1972) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.22.4.232 · Cited by 1,320
Steroid 5α-Reductase Deficiency in Man: An Inherited Form of Male Pseudohermaphroditism
Imperato-McGinley, J., Guerrero, L., Gautier, T., & Peterson, R. E. (1974) · Science · doi:10.1126/science.186.4170.1213 · Cited by 1,258
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
DUNN, J. F., NISULA, B. C., & RODBARD, D. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-53-1-58 · Cited by 1,238
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A. Y., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,234
A unified nomenclature system for the nuclear receptor superfamily
(1999) · Cell · doi:10.1016/s0092-8674(00)80726-6 · Cited by 1,208
Steroid 5α-reductase: two genes/two enzymes
Russell, D. W., & Wilson, J. D. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.000325 · Cited by 1,105
Androgen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083
Self-citationStanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Arora, V. K., Schenkein, E., Murali, R., Subudhi, S. K., Wongvipat, J., Balbas, M. D., Shah, N., Cai, L., Efstathiou, E., Logothetis, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.012 · Cited by 986
Nongenomic actions of steroid hormones
Lösel, R., & Wehling, M. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1009 · Cited by 980
Determinants of target gene specificity for steroid/thyroid hormone receptors
Umesono, K., & Evans, R. M. (1989) · Cell · doi:10.1016/0092-8674(89)90051-2 · Cited by 948
Molecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942
Role of CBP/P300 in nuclear receptor signalling
Chakravarti, D., LaMorte, V. J., Nelson, M. C., Nakajima, T., Schulman, I. G., Juguilon, H., Montminy, M., & Evans, R. M. (1996) · Nature · doi:10.1038/383099a0 · Cited by 930
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J., Wilder-Romans, K., Dhanireddy, S., Engelke, C., et al. (2014) · Nature · doi:10.1038/nature13229 · Cited by 927
Molecular Cloning of Human and Rat Complementary DNA Encoding Androgen Receptors
Chang, C. S., Kokontis, J., & Liao, S. (1988) · Science · doi:10.1126/science.3353726 · Cited by 902
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Self-citationReprogramming transcription by distinct classes of enhancers functionally defined by eRNA
Wang, D., Garcia-Bassets, I., Benner, C., Li, W., Su, X., Zhou, Y., Qiu, J., Liu, W., Kaikkonen, M. U., Ohgi, K. A., et al. (2011) · Nature · doi:10.1038/nature10006 · Cited by 827
Heemers, H. V., & Tindall, D. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0019 · Cited by 753
Self-citationSun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
Li, Y., Chan, S. C., Brand, L. J., Hwang, T. H., Silverstein, K. A. T., & Dehm, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3630 · Cited by 680
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
Carver, B. S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., Alimonti, A., Nardella, C., Varmeh, S., Scardino, P. T., et al. (2009) · Nature Genetics · doi:10.1038/ng.370 · Cited by 659
Germline Mutations in HOXB13 and Prostate-Cancer Risk
Ewing, C. M., Ray, A. M., Lange, E. M., Zuhlke, K. A., Robbins, C. M., Tembe, W. D., Wiley, K. E., Isaacs, S. D., Johng, D., Wang, Y., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110000 · Cited by 658
Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism
Andersson, S., Berman, D. M., Jenkins, E. P., & Russell, D. W. (1991) · Nature · doi:10.1038/354159a0 · Cited by 643
Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012443107 · Cited by 639
Transcriptional activation and nuclear targeting signals of the human androgen receptor.
Simental, J. A., Sar, M., Lane, M. V., French, F. S., & Wilson, E. M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52466-2 · Cited by 631
Molecular biology of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 –isomerase gene family
Simard, J., Ricketts, M.-L., Gingras, S., Soucy, P., Feltus, F. A., & Melner, M. H. (2005) · Endocrine Reviews · doi:10.1210/er.2002-0050 · Cited by 620 · cited 1×
“In peripheral tissues, including the prostate, 3b-HSD1 predominates, whereas 3bHSD2 is expressed preferentially in the adrenal glands and gonads (Simard et al. 2005).”
BackgroundSelection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin, M., Bubley, G. J., Ko, Y., Small, E. J., Upton, M. P., Rajeshkumar, B. R., & Balk, S. P. (1999) · PubMed · Cited by 596
Mostaghel, E. A., Marck, B. T., Plymate, S. R., Vessella, R. L., Balk, S., Matsumoto, A. M., Nelson, P. S., & Montgomery, R. B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0728 · Cited by 588
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577
Lin, C., Yang, L., Tanasa, B., Hutt, K., Ju, B.-G., Ohgi, K. A., Zhang, J., Rose, D. W., Fu, X.-D., Glass, C. K., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.030 · Cited by 576
Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3
Geissler, W. M., Davis, D. L., Wu, L., Bradshaw, K. D., Patel, S., Mendonca, B. B., Elliston, K. O., Wilson, J. D., Russell, D. W., & Andersson, S. (1994) · Nature Genetics · doi:10.1038/ng0594-34 · Cited by 570
Attard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H. M., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3667 · Cited by 533
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
Jenster, G., van der Korput, H. A. G. M., van Vroonhoven, C., van der Kwast, T. H., Trapman, J., & Brinkmann, A. O. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-10-1396 · Cited by 523 · cited 2×
“The LBD is vital to directing this response; this is well illustrated by the fact that a deletion of the LBD renders AR completely unresponsive to androgens (Jenster et al. 1991).”
Background(2001) · PubMed · Cited by 500
Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer
Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B., & Mohler, J. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0525 · Cited by 488
The program of androgen-responsive genes in neoplastic prostate epithelium
Nelson, P. S., Clegg, N., Arnold, H., Ferguson, C., Bonham, M., White, J., Hood, L., & Lin, B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182376299 · Cited by 482
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
King, J. C., Xu, J., Wongvipat, J., Hieronymus, H., Carver, B. S., Leung, D. H., Taylor, B. S., Sander, C., Cardiff, R. D., Couto, S. S., et al. (2009) · Nature Genetics · doi:10.1038/ng.371 · Cited by 477
Characterization and expression of a cDNA encoding the human androgen receptor.
Tilley, W. D., Marcelli, M., Wilson, J. D., & McPhaul, M. J. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.1.327 · Cited by 476
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis
Pomerantz, M. M., Li, F., Takeda, D. Y., Lenci, R., Chonkar, A., Chabot, M., Cejas, P., Vazquez, F., Cook, J., Shivdasani, R. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3419 · Cited by 470
Lubahn, D. B., Brown, T. R., Simental, J. A., Higgs, H. N., Migeon, C. J., Wilson, E. M., & French, F. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9534 · Cited by 452
A Conserved Mechanism for Steroid Receptor Translocation to the Plasma Membrane
Pedram, A., Razandi, M., Sainson, R. C. A., Kim, J. K., Hughes, C. C., & Levin, E. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611877200 · Cited by 446
Veldscholte, J., Berrevoets, C. A., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Trapman, J., Brinkmann, A. O., & Mulder, E. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90401-4 · Cited by 446
He, B., Kemppainen, J. A., & Wilson, E. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002807200 · Cited by 442
Culig, Z. (1993) · Molecular Endocrinology · doi:10.1210/me.7.12.1541 · Cited by 440
The human glucocorticoid receptor: molecular basis of biologic function
Nicolaides, N. C., Galata, Z., Kino, T., Chrousos, G. P., & Charmandari, E. (2010) · Steroids · doi:10.1016/j.steroids.2009.09.002 · Cited by 436
TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion
Perner, S., Mosquera, J.-M., Demichelis, F., Hofer, M. D., Paris, P. L., Simko, J., Collins, C., Bismar, T. A., Chinnaiyan, A. M., De Marzo, A. M., et al. (2007) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213424.38503.aa · Cited by 426
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M., & Miyamoto, M. (2003) · PubMed · Cited by 425
Zhou, Z. X. (1995) · Molecular Endocrinology · doi:10.1210/me.9.2.208 · Cited by 411
Culig, Z., Hoffmann, J., Erdel, M., Eder, I. E., Hobisch, A., Hittmair, A., Bartsch, G., Utermann, G., Schneider, M. R., Parczyk, K., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690684 · Cited by 409
Sharma, N. L., Massie, C. E., Ramos-Montoya, A., Zecchini, V., Scott, H. E., Lamb, A. D., MacArthur, S., Stark, R., Warren, A. Y., Mills, I. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.010 · Cited by 405
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Scher, H. I., & Kelly, W. K. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1566 · Cited by 405
The intranuclear binding of testosterone and 5α-androstan-17β-ol-3-one by rat prostate
Bruchovsky, N., & Wilson, J. D. (1968) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)94513-8 · Cited by 404
Structural basis of androgen receptor binding to selective androgen response elements
Shaffer, P. L., Jivan, A., Dollins, D. E., Claessens, F., & Gewirth, D. T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401123101 · Cited by 400
Overcoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. A., Chen, Y., Greene, G. L., Shen, Y., & Sawyers, C. L. (2013) · eLife · doi:10.7554/elife.00499 · Cited by 397
Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer
Mani, R.-S., Tomlins, S. A., Callahan, K., Ghosh, A., Nyati, M. K., Varambally, S., Palanisamy, N., & Chinnaiyan, A. M. (2009) · Science · doi:10.1126/science.1178124 · Cited by 391
ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice
Tomlins, S. A., Bjartell, A., Chinnaiyan, A. M., Jenster, G., Nam, R. K., Rubin, M. A., & Schalken, J. A. (2009) · European Urology · doi:10.1016/j.eururo.2009.04.036 · Cited by 381
Akakura, K., Bruchovsky, N., Goldenberg, S. L., Rennie, P. S., Buckley, A. R., & Sullivan, L. D. (1993) · Cancer · doi:10.1002/1097-0142(19930501)71:9<2782::aid-cncr2820710916>3.0.co;2-z · Cited by 373
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364
Taplin, M.-E., Rajeshkumar, B., Halabi, S., Werner, C. P., Woda, B. A., Picus, J., Stadler, W., Hayes, D. F., Kantoff, P. W., Vogelzang, N. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.102 · Cited by 364
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
Chang, K.-H., Li, R., Papari-Zareei, M., Watumull, L., Zhao, Y. D., Auchus, R. J., & Sharifi, N. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107898108 · Cited by 346
Self-citationMellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344 · cited 2×
“…receptors, insulin-like growth factor 1 (IGF-1) receptor, and Her2/neu have been implicated in cross talk with AR to drive ligandindependent signaling or to sensitize AR to subphysiologic androgen concentrations (Mellinghoff et al. 2004; Guo et al. 2006; Ponguta et al. 2008; Dutt and Gao 2009).”
BackgroundMolecular regulation of androgen action in prostate cancer.
Dehm, S. M., & Tindall, D. J. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20794 · Cited by 336
(1994) · PubMed Central · Cited by 328
Mechanisms of the androgen receptor splicing in prostate cancer cells
Liu, L. L., Xie, N., Sun, S., Plymate, S., Mostaghel, E., & Dong, X. (2014) · Oncogene · doi:10.1038/onc.2013.284 · Cited by 315
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Chang, K.-H., Li, R., Kuri, B., Lotan, Y., Roehrborn, C. G., Liu, J., Vessella, R., Nelson, P. S., Kapur, P., Guo, X., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.029 · Cited by 312
Self-citationWilson, E. M., & French, F. S. (1976) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)33103-4 · Cited by 311
Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
Knudsen, K. E., & Scher, H. I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2660 · Cited by 307
Taplin, M.-E., Montgomery, B., Logothetis, C. J., Bubley, G. J., Richie, J. P., Dalkin, B. L., Sanda, M. G., Davis, J. W., Loda, M., True, L. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.4578 · Cited by 284
Attard, G., Reid, A. H. M., Auchus, R. J., Hughes, B. A., Cassidy, A. M., Thompson, E., Oommen, N. B., Folkerd, E., Dowsett, M., Arlt, W., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2189 · Cited by 282
Gregory, C. W., Hamil, K. G., Kim, D., Hall, S. H., Pretlow, T. G., Mohler, J. L., & French, F. S. (1998) · PubMed · Cited by 275
An, J., Wang, C., Deng, Y., Yu, L., & Huang, H. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.01.013 · Cited by 260
Peptidomimetic targeting of critical androgen receptor–coregulator interactions in prostate cancer
Ravindranathan, P., Lee, T.-K., Yang, L., Centenera, M. M., Butler, L., Tilley, W. D., Hsieh, J.-T., Ahn, J.-M., & Raj, G. V. (2013) · Nature Communications · doi:10.1038/ncomms2912 · Cited by 257
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Li, Z., Bishop, A. C., Alyamani, M., Garcia, J. A., Dreicer, R., Bunch, D., Liu, J., Upadhyay, S. K., Auchus, R. J., & Sharifi, N. (2015) · Nature · doi:10.1038/nature14406 · Cited by 256
Self-citationSchweizer, M. T., Antonarakis, E. S., Wang, H., Ajiboye, A. S., Spitz, A., Cao, H., Luo, J., Haffner, M. C., Yegnasubramanian, S., Carducci, M. A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010563 · Cited by 254
Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines
Mohler, J. L., Armstrong, A. J., Bahnson, R. R., Boston, B., Busby, J. E., D’Amico, A. V., Eastham, J. A., Enke, C. A., Farrington, T., Higano, C. S., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0114 · Cited by 251
5α-reductase activity in the prostate
Steers, W. D. (2001) · Urology · doi:10.1016/s0090-4295(01)01299-7 · Cited by 247
SRC-3 Is Required for Prostate Cancer Cell Proliferation and Survival
Zhou, H.-J., Yan, J., Luo, W., Ayala, G., Lin, S.-H., Erdem, H., Ittmann, M., Tsai, S. Y., & Tsai, M.-J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4076 · Cited by 246
Androgen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically
Ryan, C. J., & Tindall, D. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2005 · Cited by 244
Sadi, M. V., Walsh, P. C., & Barrack, E. R. (1991) · Cancer · doi:10.1002/1097-0142(19910615)67:12<3057::aid-cncr2820671221>3.0.co;2-s · Cited by 240
Deslypere, J.-P., Young, M., Wilson, J. D., & McPhaul, M. J. (1992) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(92)90004-p · Cited by 232
FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells
Sahu, B., Laakso, M., Pihlajamaa, P., Ovaska, K., Sinielnikov, I., Hautaniemi, S., & Jänne, O. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2350 · Cited by 232
Diverse roles of androgen receptor (AR) domains in AR-mediated signaling
Claessens, F., Denayer, S., Van Tilborgh, N., Kerkhofs, S., Helsen, C., & Haelens, A. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06008 · Cited by 231
Araujo, J. C., Trudel, G. C., Saad, F., Armstrong, A. J., Yu, E. Y., Bellmunt, J., Wilding, G., McCaffrey, J., Serrano, S. V., Matveev, V. B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70479-0 · Cited by 231
Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men
Page, S. T., Lin, D. W., Mostaghel, E. A., Hess, D. L., True, L. D., Amory, J. K., Nelson, P. S., Matsumoto, A. M., & Bremner, W. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0968 · Cited by 229
Nishiyama, T., Hashimoto, Y., & Takahashi, K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0913 · Cited by 223
Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation
Claessens, F., Verrijdt, G., Schoenmakers, E., Haelens, A., Peeters, B., Verhoeven, G., & Rombauts, W. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00154-0 · Cited by 222
Androgen Resistance — The Clinical and Molecular Spectrum
Flier, J. S., Underhill, L. H., & Griffin, J. E. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202273260906 · Cited by 220
p300 in prostate cancer proliferation and progression.
Debes, J. D., Sebo, T. J., Lohse, C. M., Murphy, L. M., Haugen, D. A. L., & Tindall, D. J. (2003) · PubMed · Cited by 219
Berrevoets, C. A. (1998) · Molecular Endocrinology · doi:10.1210/me.12.8.1172 · Cited by 212
Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone
Askew, E. B., Gampe, R. T., Stanley, T. B., Faggart, J. L., & Wilson, E. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703268200 · Cited by 210
Doesburg, P., Kuil, C. W., Berrevoets, C. A., Steketee, K., Faber, P. W., Mulder, E., Brinkmann, A. O., & Trapman, J. (1997) · Biochemistry · doi:10.1021/bi961775g · Cited by 209
Li, Y., Hwang, T. H., Oseth, L. A., Hauge, A., Vessella, R. L., Schmechel, S. C., Hirsch, B., Beckman, K. B., Silverstein, K. A., & Dehm, S. M. (2012) · Oncogene · doi:10.1038/onc.2011.637 · Cited by 202
Fleshner, N. E., Lucia, M. S., Egerdie, B., Aaron, L., Eure, G., Nandy, I., Black, L., & Rittmaster, R. S. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61619-x · Cited by 201
Li, Y., Alsagabi, M., Fan, D., Bova, G. S., Tewfik, A. H., & Dehm, S. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1998 · Cited by 199
Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.
Umekita, Y., Hiipakka, R. A., Kokontis, J. M., & Liao, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11802 · Cited by 195
Cao, B., Qi, Y., Zhang, G., Xu, D., Zhan, Y., Alvarez, X., Guo, Z., Fu, X., Plymate, S. R., Sartor, O., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1802 · Cited by 194
Ferraldeschi, R., Welti, J., Luo, J., Attard, G., & de Bono, J. S. (2015) · Oncogene · doi:10.1038/onc.2014.115 · Cited by 192
Geng, C., Rajapakshe, K., Shah, S. S., Shou, J., Eedunuri, V. K., Foley, C., Fiskus, W., Rajendran, M., Chew, S. A., Zimmermann, M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0476 · Cited by 190
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer
Gnanapragasam, V. J., Leung, H. Y., Pulimood, A. S., Neal, D. E., & Robson, C. N. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2179 · Cited by 189
The FXXLF Motif Mediates Androgen Receptor-specific Interactions with Coregulators
He, B., Minges, J. T., Lee, L. W., & Wilson, E. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111975200 · Cited by 189
Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes
Xu, D., Zhan, Y., Qi, Y., Cao, B., Bai, S., Xu, W., Gambhir, S. S., Lee, P., Sartor, O., Flemington, E. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0381 · Cited by 189
Sato, N., Gleave, M. E., Bruchovsky, N., Rennie, P. S., Goldenberg, S. L., Lange, P. H., & Sullivan, L. D. (1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(96)00018-0 · Cited by 184
The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
Ziada, A., Barqawi, A., Glode, L. M., Varella‐Garcia, M., Crighton, F., Majeski, S., Rosenblum, M., Kane, M., Chen, L., & Crawford, E. D. (2004) · The Prostate · doi:10.1002/pros.20065 · Cited by 181
Collocation of androgen receptor gene mutations in prostate cancer.
Buchanan, G., Greenberg, N. M., Scher, H. I., Harris, J. M., Marshall, V. R., & Tilley, W. D. (2001) · PubMed · Cited by 181
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer
Hofland, J., van Weerden, W. M., Dits, N. F. J., Steenbergen, J., van Leenders, G. J. L. H., Jenster, G., Schröder, F. H., & de Jong, F. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2092 · Cited by 176
Smith, D. F., & Toft, D. O. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0089 · Cited by 173
Maintaining and reprogramming genomic androgen receptor activity in prostate cancer
Mills, I. G. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3678 · Cited by 172
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
Li, Z., Alyamani, M., Li, J., Rogacki, K., Abazeed, M., Upadhyay, S. K., Balk, S. P., Taplin, M.-E., Auchus, R. J., & Sharifi, N. (2016) · Nature · doi:10.1038/nature17954 · Cited by 171
Self-citationBufalin Is a Potent Small-Molecule Inhibitor of the Steroid Receptor Coactivators SRC-3 and SRC-1
Wang, Y., Lonard, D. M., Yu, Y., Chow, D.-C., Palzkill, T. G., Wang, J., Qi, R., Matzuk, A. J., Song, X., Madoux, F., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2939 · Cited by 168
Androgen Receptor Nuclear Translocation Is Facilitated by the f-Actin Cross-Linking Protein Filamin
Ozanne, D. M., Brady, M. E., Cook, S., Gaughan, L., Neal, D. E., & Robson, C. N. (2000) · Molecular Endocrinology · doi:10.1210/me.14.10.1618 · Cited by 162
Ware, K. E., García-Blanco, M. A., Armstrong, A. J., & Dehm, S. M. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0470 · Cited by 158
Asangani, I. A., Wilder-Romans, K., Dommeti, V. L., Krishnamurthy, P. M., Apel, I. J., Escara-Wilke, J., Plymate, S. R., Navone, N. M., Wang, S., Feng, F. Y., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0472 · Cited by 158
Chan, S. C., Selth, L. A., Li, Y., Nyquist, M. D., Lu, M., Bradner, J. E., Raj, G. V., Tilley, W. D., & Dehm, S. M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv262 · Cited by 155
Thigpen, A. E., Cala, K. M., & Russell, D. W. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85349-8 · Cited by 152
Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus
Thadani‐Mulero, M., Nanus, D. M., & Giannakakou, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0783 · Cited by 151
Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer
Lamont, K. R., & Tindall, D. J. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0469 · Cited by 150
Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights
Byrns, M. C., Jin, Y., & Penning, T. M. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.11.004 · Cited by 147
AKR1C3 as a target in castrate resistant prostate cancer
Adeniji, A. O., Chen, M., & Penning, T. M. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.05.012 · Cited by 143
Hearn, J. W. D., AbuAli, G., Reichard, C. A., Reddy, C. A., Magi‐Galluzzi, C., Chang, K., Carlson, R. E., Rangel, L. J., Reagan, K., Davis, B. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30227-3 · Cited by 142
Self-citationBono, J. S. D., Joaquim Bellmunt, B., Attard, G., Droz, J. P., Miller, K., Fléchon, A., Sternberg, C. N., Parker, C. C., Zugmaier, G., Hersberger-Gimenez, V., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0888 · Cited by 141
Steroid 5alpha-reductase deficiency in man. An inherited form of male pseudohermaphroditism.
Imperato‐McGinley, J., Guerrero, L., Gautier, T., Jl, G., & Peterson, R. E. (1975) · PubMed · Cited by 135
Dalal, K., Roshan‐Moniri, M., Sharma, A., Li, H., Ban, F., Hessein, M., Hsing, M., Singh, K., Leblanc, E., Dehm, S. M., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.553818 · Cited by 135
Molecular Mechanisms of Castration-Resistant Prostate Cancer Progression
Dutt, S. S., & Gao, A. C. (2009) · Future Oncology · doi:10.2217/fon.09.117 · Cited by 130
Nakamura, Y., Hornsby, P. J., Casson, P., Morimoto, R., Satoh, F., Xing, Y., Kennedy, M. R., Sasano, H., & Rainey, W. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2374 · Cited by 129
Are androgen receptor variants a substitute for the full-length receptor?
Ji, L., der Steen, T. V., & Tindall, D. J. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.13 · Cited by 128
DHT Concentrations in Human Prostate Cancer Tissue*
Geller, J., ALBERT, J. D., Loza, D., Geller, S., Stoeltzing, W., & DANIEL, D. L. V. (1978) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-46-3-440 · Cited by 128
Li, J., Alyamani, M., Zhang, A., Chang, K., Berk, M. P., Li, Z., Zhu, Z., Petro, M., Magi‐Galluzzi, C., Taplin, M., et al. (2017) · eLife · doi:10.7554/elife.20183 · Cited by 128
Self-citationLitvinov, I. V., Griend, D. J. V., Antony, L., Dalrymple, S. L., Marzo, A. M. D., Drake, C. G., & Isaacs, J. T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603057103 · Cited by 126
Differential Requirement of SWI/SNF for Androgen Receptor Activity
Marshall, T. W., Link, K. A., Petre, C. E., & Knudsen, K. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304582200 · Cited by 125
Small Molecule Inhibition of the Steroid Receptor Coactivators, SRC-3 and SRC-1
Wang, Y., Lonard, D. M., Yu, Y., Chow, D., Palzkill, T. G., & O’Malley, B. W. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-1222 · Cited by 122
Denmeade, S. R., & Isaacs, J. T. (2010) · The Prostate · doi:10.1002/pros.21196 · Cited by 122
Chuu, C., Hiipakka, R. A., Fukuchi, J., Kokontis, J. M., & Liao, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3992 · Cited by 121
Type 1 and Type 2 5α-Reductase Expression in the Development and Progression of Prostate Cancer
Thomas, L. N., Douglas, R. C., Lazier, C. B., Too, C. K. L., Rittmaster, R. S., & Tindall, D. J. (2007) · European Urology · doi:10.1016/j.eururo.2007.10.052 · Cited by 118
Steroid biosynthesis and prostate cancer
Sharifi, N., & Auchus, R. J. (2012) · Steroids · doi:10.1016/j.steroids.2012.03.015 · Cited by 116
Self-citationPonguta, L. A., Gregory, C. W., French, F. S., & Wilson, E. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802392200 · Cited by 115
Androgen receptor gene mutations in hormone-refractory prostate cancer
Wall�n, M., Linja, M. J., Kaartinen, K., Schleutker, J., & Visakorpi, T. (1999) · The Journal of Pathology · Cited by 115
Isaacs, J. T., D’Antonio, J. M., Chen, S., Antony, L., Dalrymple, S. P., Ndikuyeze, G. H., Luo, J., & Denmeade, S. R. (2012) · The Prostate · doi:10.1002/pros.22504 · Cited by 113
Ianculescu, I., Wu, D., Siegmund, K. D., & Stallcup, M. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.300194 · Cited by 110
Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation.
Liao, R. S., Ma, S., Lu, M., Li, R., Yin, Y., & Raj, G. V. (2013) · PubMed Central · doi:10.3978/j.issn.2223-4683.2013.09.07 · Cited by 107
5α‐Reductase Isozymes and Androgen Actions in the Prostate
Zhu, Y., & Imperato‐McGinley, J. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04115.x · Cited by 107
Castration-recurrent prostate cancer is not androgen-independent.
Mohler, J. L. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_21 · Cited by 106
Sex hormone-binding globulin: Anatomy and physiology of a new regulatory system
Rosner, W., Hryb, D. J., Khan, M., Nakhla, A. M., & Romas, N. A. (1991) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(91)90307-q · Cited by 106
Park, K., Dalton, J. T., Narayanan, R., Barbieri, C. E., Hancock, M. L., Bostwick, D. G., Steiner, M. S., & Rubin, M. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.8386 · Cited by 106
Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers
Xu, Y. J., Dalrymple, S. L., Becker, R. E., Denmeade, S. R., & Isaacs, J. T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0184 · Cited by 105
The role of 5α-reduction in steroid hormone physiology
Wilson, J. D. (2002) · Reproduction Fertility and Development · doi:10.1071/rd01074 · Cited by 104
Sedelaar, J. P. M., & Isaacs, J. T. (2009) · The Prostate · doi:10.1002/pros.21028 · Cited by 97
Mechanisms of Androgen Receptor Activation in Castration-Resistant Prostate Cancer
Sharifi, N. (2013) · Endocrinology · doi:10.1210/en.2013-1466 · Cited by 97
Self-citationTargeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study
Mostaghel, E. A., Nelson, P. S., Lange, P. H., Lin, D. W., Taplin, M. E., Balk, S. P., Ellis, W., Kantoff, P. W., Marck, B. T., Tamae, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.6431 · Cited by 87
Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
Chuu, C., Kokontis, J. M., Hiipakka, R. A., Fukuchi, J., Lin, H., Lin, C., Huo, C., & Su, L. (2011) · Journal of Biomedical Science · doi:10.1186/1423-0127-18-63 · Cited by 86
Modulation of Androgen Receptor by FOXA1 and FOXO1 Factors in Prostate Cancer
Zhao, Y., Tindall, D. J., & Huang, H. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.8389 · Cited by 86
Steroid hormone synthetic pathways in prostate cancer.
Mostaghel, E. A. (2013) · PubMed Central · doi:10.3978/j.issn.2223-4683.2013.09.16 · Cited by 85
Forti, G., SALERNO, R., Moneti, G., ZOPPI, S., Fiorelli, G., MARINONI, T., Natali, A., COSTANTINI, A., Serio, M., Martini, L., et al. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-2-461 · Cited by 83
Griend, D. J. V., Litvinov, I. V., & Isaacs, J. T. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.8756 · Cited by 83
Evaul, K., Li, R., Papari-Zareei, M., Auchus, R. J., & Sharifi, N. (2010) · Endocrinology · doi:10.1210/en.2010-0138 · Cited by 82
Self-citationAndrogen Induces a Switch from Cytoplasmic Retention to Nuclear Import of the Androgen Receptor
Ni, L., Llewellyn, R. A., Kesler, C. T., Kelley, J. B., Spencer, A., Snow, C. J., Shank, L. C., & Paschal, B. M. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00647-13 · Cited by 81
Stabilizing Androgen Receptor in Mitosis Inhibits Prostate Cancer Proliferation
Griend, D. J. V., Litvinov, I. V., & Isaacs, J. T. (2007) · Cell Cycle · doi:10.4161/cc.6.6.4028 · Cited by 78
Page, S. T., Lin, D. W., Mostaghel, E. A., Marck, B. T., Wright, J. L., Wu, J. D., Amory, J. K., Nelson, P. S., & Matsumoto, A. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1865 · Cited by 78
Serum/glucocorticoid‐regulated kinase 1 expression in primary human prostate cancers
Szmulewitz, R. Z., Chung, E. K., Al‐Ahmadie, H. A., Daniel, S., Kocherginsky, M., Razmaria, A. A., Zagaja, G. P., Brendler, C. B., Stadler, W. M., & Conzen, S. D. (2011) · The Prostate · doi:10.1002/pros.21416 · Cited by 77
5alpha-reductase: history and clinical importance.
Marks, L. S. (2004) · Europe PMC (PubMed Central) · Cited by 75
Ryan, C. J., Smith, A., Lal, P., Satagopan, J. M., Reuter, V. E., Scardino, P. T., Gerald, W. L., & Scher, H. I. (2006) · Urology · doi:10.1016/j.urology.2006.04.016 · Cited by 72
Chuu, C., Kokontis, J. M., Hiipakka, R. A., Fukuchi, J., Lin, H., Lin, C., Huo, C., Su, L., & Liao, S. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02043.x · Cited by 70
Androgen Modulation of Coregulator Expression in Prostate Cancer Cells
Heemers, H. V., Regan, K. M., Schmidt, L. J., Anderson, S. K., Ballman, K. V., & Tindall, D. J. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0363 · Cited by 69
Self-citationCoactivator selective regulation of androgen receptor activity
Agoulnik, I. U., & Weigel, N. L. (2009) · Steroids · doi:10.1016/j.steroids.2009.02.007 · Cited by 64
Rittmaster, R. S., Hahn, R. G., Ray, P., Shannon, J. B., & Wurzel, R. S. (2008) · Urology · doi:10.1016/j.urology.2008.06.032 · Cited by 63
Rittmaster, R. S. (1997) · Journal of Andrology · doi:10.1002/j.1939-4640.1997.tb02434.x · Cited by 63
Sedelaar, J. P. M., Dalrymple, S. L., & Isaacs, J. T. (2013) · The Prostate · doi:10.1002/pros.22677 · Cited by 60
Kaku, N., Matsuda, K.-I., Tsujimura, A., & Kawata, M. (2008) · Endocrinology · doi:10.1210/en.2008-0137 · Cited by 58
Labrie, F., Dupont, A., Simard, J., Luu-The, V., & Bèlanger, A. (1993) · European Urology · doi:10.1159/000474399 · Cited by 58
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
Mostaghel, E. A. (2014) · Cancer Management and Research · doi:10.2147/cmar.s39318 · Cited by 57
Nishiyama, T. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.03.007 · Cited by 57
Rittmaster, R. S. (1998) · PubMed · Cited by 55
Phase II Study of Dutasteride for Recurrent Prostate Cancer During Androgen Deprivation Therapy
Shah, S. K., Trump, D. L., Sartor, O. A., Tan, W., Wilding, G. E., & Mohler, J. L. (2008) · The Journal of Urology · doi:10.1016/j.juro.2008.10.014 · Cited by 54
Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer
Schmidt, L. J., & Tindall, D. J. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.09.003 · Cited by 48
Shiota, M., Yokomizo, A., Fujimoto, N., & Naito, S. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911796798904 · Cited by 48
Beyond T and DHT - Novel Steroid Derivatives Capable of Wild Type Androgen Receptor Activation
Mostaghel, E. A. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.8844 · Cited by 46
Zhang, A., Zhang, J., Plymate, S. R., & Mostaghel, E. A. (2016) · Hormones and Cancer · doi:10.1007/s12672-016-0250-9 · Cited by 43
Role of 5α-Reductase Inhibitors in Prostate Cancer Prevention and Treatment
Azzouni, F. S., & Mohler, J. L. (2012) · Urology · doi:10.1016/j.urology.2012.01.024 · Cited by 42
DePriest, A. D., Fiandalo, M. V., Schlanger, S. E., Heemers, F., Mohler, J. L., Liu, S., & Heemers, H. V. (2016) · Database · doi:10.1093/database/bav125 · Cited by 35
Self-citationNew agents and strategies for the hormonal treatment of castration-resistant prostate cancer
Sharifi, N. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.494178 · Cited by 32
Self-citation
Cited by
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715546 · Cited by 1,344
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
Hormonal Therapy for Prostate Cancer
Desai, K., McManus, J. M., & Sharifi, N. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab002 · Cited by 447
Self-citationEpidemiology and genomics of prostate cancer in Asian men
Zhu, Y., Mo, M., Wei, Y., Wu, J., Pan, J., Freedland, S. J., Zheng, Y., & Ye, D. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00442-8 · Cited by 287
Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256
Metadata
- Authors
- Dai, C., Heemers, H., & Sharifi, N.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-04-07
- Volume
- 7
- Issue
- 9
- Pages
- a030452
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2605070587
- Cited by
- 406
- References
- 212
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.